Donor Lymphocyte Infusion Post Transplant
Phase I/II Study Using Prophylactic Donor Lymphocyte Infusion Early Post-Transplant After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for High-Risk Hematologic Malignancies
What's the purpose of the trial?
Accepting patients
For Healthcare Professionals Only
This site is intended for healthcare professionals in the US. Patients and care partners can explore and connect with MDS clinical trials through our patient portal.

Participating Centers
There is one center participating in this trial. Enter a location below to view the distance.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body, and may be used in the treatment of many different cancers.
- Cyclophosphamide is a chemotherapy agent used in the treatment of cancer.
- Donor Lymphocyte Infusion (DLI) is an infusion of lymphocytes (usually T cells) that come from a donor.
- Fludarabine is a chemotherapy medication that may be used in the treatment of many different cancers.
- Mycophenolate Mofetil is an immunosuppressive medication used to help prevent rejection in patients who have had a transplant.
- Sirolimus is an immunosuppressive medication used in several indications, including to help prevent rejection in patients who have had a transplant.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.